MedStone Pharmaceuticals LLC

What MedStone Pharmaceuticals LLC does

MedStone Pharmaceuticals LLC (d/b/a MedStone Pharma) is a privately held, Florida-based specialty generic pharmaceutical company that develops, manufactures, and distributes FDA-approved generic medications across immunology, oncology, dermatology, and central nervous system therapeutic areas. Its named product portfolio includes Pin Para IG (immunoglobulin, 5g/100ml), LenalidoMed lenalidomide 10 mg and 15 mg, Zolmitriptan 2.5 mg and 5 mg, Sumatriptan, Para CBD 45 mg transdermal patches, and the Para VITADEK softgel and drop dietary supplement line approved by ANVISA for Brazil. The R&D pipeline targets differentiated dosage forms — nasal sprays, injectables, oncology, dermatology, and metered-dose inhalers — with stated interest in first-to-file and 505(b)(2) opportunities.

Operationally, MedStone runs a fully integrated stack spanning discovery research, process chemistry, formulation development, and commercialization, underpinned by full Drug Supply Chain Security Act (DSCSA) compliance with end-to-end serialization and EDI integration. Distribution is delivered through a 3PL network covering all 50 U.S. states and international markets, supported by 50+ sales representatives.

The commercial model combines three revenue streams: direct generic product sales, licensing income from in-licensing and out-licensing agreements (including ANDA licensing, co-development, and authorized generics), and government contracts with federal agencies — specifically the Department of Veterans Affairs, Department of Defense (including DAPA #SP0200-26-H-0011), and Department of Health and Human Services. The company holds multiple federal credentials (UEI, DUNS, CAGE Code, VA certifications) and serves a stated base of 8,000+ active customers across both commercial healthcare providers and public-sector channels.

Name

MedStone Pharmaceuticals LLC

Legal name

MedStone Pharmaceuticals LLC

Website

https://medstonepharma.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

MedStone Pharmaceuticals LLC is a Florida-based specialty generic pharmaceutical developer and distributor serving U.S. federal agencies (VA, DoD, HHS), commercial healthcare providers, and select international markets with a portfolio spanning migraine, oncology, immunoglobulin, dermatology, and dietary supplement products, supported by DSCSA-compliant nationwide 3PL distribution.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Specialty medications
• Immunoglobulin therapy
• Migraine treatments
• Prescription distribution

Headquarters

HQ city

Flushing

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Revenue generated from developing, manufacturing, and distributing generic pharmaceutical products across therapeutic areas including immunology, oncology, dermatology, and central nervous system medications. Products are sold to commercial markets, government agencies, and healthcare providers.
2. Licensing Agreements: Revenue from strategic in-licensing and out-licensing agreements across the United States and international markets, including ANDA licensing, co-development initiatives, and commercialization of Authorized Generics.
3. Government Contracts: Revenue from supplying pharmaceutical products to federal, state, and local government agencies including the Department of Veterans Affairs (VA), Department of Defense (DoD), and Department of Health and Human Services (HHS).

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

MedStone Pharmaceuticals LLC develops, manufactures, and distributes a portfolio of generic pharmaceutical products across multiple therapeutic areas, including immunoglobulin (Pin Para IG 5g/100 ml), migraine therapies (Zolmitriptan 2.5 mg, Zolmitriptan 5 mg, Sumatriptan), oncology drugs (LenalidoMed 10 mg and 15 mg Lenalidomide), dermatology products, CBD patches (Para CBD 45 mg), and dietary supplements (Para VITADEK softgels and drops). The company serves U.S. federal government agencies (VA, DoD, HHS) and a commercial base of more than 8,000 healthcare providers through direct sales, a 3PL network, and licensing partnerships.

Product overview

MedStone Pharma is a specialty generic pharmaceutical company that develops, manufactures, and delivers cost-effective generic medications across multiple therapeutic areas. Their product portfolio includes a diversified range of generic pharmaceuticals spanning therapeutic areas including immunology (Pin Para IG), dietary supplements (VITADEK line for the Brazilian market), dermatology/topicals (CBD patches), neurology/migraine treatments (Zolmitriptan and Sumatriptan), and oncology (Lenalidomide). The company operates across commercial markets, federal agencies, and all sectors of government, with an R&D pipeline targeting nasal sprays, injectables, oncology, dermatology, and metered-dose inhalers. Their fully integrated approach spans discovery research, process chemistry, formulation development, and commercialization, with nationwide distribution across all 50 U.S. states.

Differentiator

Problem solved

Functional benefit

Products and services

• Pin Para IG 5g/100 ml Generic immunoglobulin (IG) therapy product at 5g/100 ml dosage, sold to government agencies and commercial healthcare providers for immune deficiency and related indications.
• Zolmitriptan 2.5 mg Generic triptan medication at 2.5 mg dosage for the acute treatment of migraine, distributed to healthcare providers and government buyers.
• Zolmitriptan 5 mg Generic triptan medication at 5 mg dosage for the acute treatment of migraine, distributed to healthcare providers and government buyers.
• Sumatriptan Generic sumatriptan therapy for the acute treatment of migraine and cluster headaches, distributed through MedStone's commercial and government channels.
• LenalidoMed 10 mg (Lenalidomide) Generic lenalidomide 10 mg oncology therapy indicated for multiple myeloma and related conditions, distributed to oncology providers and government healthcare agencies.
• LenalidoMed 15 mg (Lenalidomide) Generic lenalidomide 15 mg oncology therapy indicated for multiple myeloma and related conditions, distributed to oncology providers and government healthcare agencies.
• Para CBD 45 mg Patches 45 mg CBD transdermal patch sold under the Para CBD brand for topical/wearable cannabinoid delivery, distributed through MedStone's commercial and partner channels.
• Para VITADEK Softgels (60 softgels) Vitamin/dietary supplement softgel product, 60-count packaging, registered with ANVISA (Brazil) and distributed through MedStone's licensing partnership channel.
• Para VITADEK Drops (60 ml) Liquid vitamin/dietary supplement drops product, 60 ml packaging, registered with ANVISA (Brazil) and distributed through MedStone's licensing partnership channel.

Quantifiable outcome

• Generic drugs cost 30-80% less than brand-name equivalents while delivering identical therapeutic benefits
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Large Pharmaceutical CompaniescoreStrategic or Co-development PartnerStrategic partnerships with large pharmaceutical companies to expand product portfolio and market reach through product acquisitions, ANDA licensing, co-development initiatives, and authorized generics commercialization. MedStone combines its technical expertise with partner sales and marketing capabilities.
• Specialty Pharma CompaniescoreStrategic or Co-development PartnerPartnerships with specialty pharmaceutical companies focused on niche medications and differentiated products, leveraging MedStone's fully integrated capabilities from discovery through commercialization.
• Generic ManufacturerscoreStrategic or Co-development PartnerCollaborative relationships with generic manufacturers for co-development initiatives, ANDA licensing, and product acquisitions to drive portfolio expansion and market penetration across commercial and government markets.
• 3PL Logistics PartnerscoreChannel Partner/ Reseller/ DistributorThird-party logistics partners enabling nationwide distribution across all 50 states and international markets, with full DSCSA compliance, EDI integration, and product serialization capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: India-headquartered global generics leader with a US subsidiary (Caraco/Sun) covering CNS, oncology, and immunology. Sun's US generic footprint provides the established alternative for many of the same molecules MedStone targets.
• Sandoz (Novartis): Major global generics and biosimilars player with deep presence across CNS, oncology, and immunology, including differentiated generics and inhalation products. Sandoz's differentiation and biosimilars focus overlaps with MedStone's pipeline (MDIs, oncology, injectables).
• Viatris Inc. One of the largest global generics manufacturers (formed from Mylan/Pfizer Upjohn), offering a broad portfolio overlapping MedStone's CNS (Sumatriptan/Zolmitriptan) and oncology (Lenalidomide) franchises. Viatris is the incumbent benchmark for off-patent oral solid generics and biologic adjacencies.
• Teva Pharmaceutical Industries: The world's largest generic manufacturer with extensive coverage of CNS, oncology, and immunology molecules that overlap with MedStone's marketed portfolio and pipeline. Teva sets the price/volume reference point across most generic therapeutic areas MedStone competes in.

Direct peers

• Amneal Pharmaceuticals: US-headquartered generic and specialty pharmaceutical company with products in CNS (including migraine), oncology, and immunology, plus increasing exposure to injectables and inhalation. Amneal's specialty generics business mirrors MedStone's diversified, partnership-heavy model.
• Apotex Inc. Large privately held generic pharmaceutical manufacturer with a broad portfolio across multiple therapeutic areas including oncology, CNS, and immunology. Apotex operates a fully integrated discovery-to-commercial model and competes with MedStone in generic ANDAs, government supply, and partnership-driven product development.
• Perrigo Company: US-based manufacturer and distributor of generic prescription and OTC pharmaceuticals, including neurology, dermatology, and immunology products. Perrigo's generic Rx model and customer-base scale match MedStone's go-to-market and customer count profile.
• Endo International (Par Pharmaceutical): Through Par, Endo operates one of the largest US generic businesses with strength in injectables, oncology, and specialty generics. Par's injectables franchise directly parallels MedStone's injectable pipeline strategy.
• Aurobindo Pharma: Vertically integrated generic pharmaceutical manufacturer with a broad ANDA portfolio spanning CNS, oncology, and dermatology. Aurobindo competes directly with MedStone on generic ANDAs and government supply at US scale.
• Lupin Pharmaceuticals: Global generic manufacturer with significant US presence across CNS, oncology, and dermatology. Lupin's complex generics and biosimilars pipeline aligns with MedStone's move toward differentiated dosage forms and specialty oncology products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/MedStone_Pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedStone Pharmaceuticals LLC